Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00848926 · OUTCOME

Chemistry Laboratory Abnormalities >/= Grade 3

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma · Source last updated 2017-03-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
up to 12 months

What was measured

Counts of study participants with post-baseline chemistry laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 3.0. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category.

Analysis population: All participants who received treatment

Groups in this outcome

Brentuximab Vedotin

Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Brentuximab Vedotin102

Reported measurements

Any >/= Grade 3 chemistry laboratory abnormality
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Brentuximab Vedotin14Not reportedNot reportedNot reportedNot reported
Alanine aminotransferase (high)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Brentuximab Vedotin1Not reportedNot reportedNot reportedNot reported
Albumin (low)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Brentuximab Vedotin1Not reportedNot reportedNot reportedNot reported
Calcium (low)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Brentuximab Vedotin1Not reportedNot reportedNot reportedNot reported
Glucose (high)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Brentuximab Vedotin7Not reportedNot reportedNot reportedNot reported
Potassium (low)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Brentuximab Vedotin2Not reportedNot reportedNot reportedNot reported
Sodium (high)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Brentuximab Vedotin1Not reportedNot reportedNot reportedNot reported
Urate (high)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Brentuximab Vedotin1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        14
    title
    Any >/= Grade 3 chemistry laboratory abnormality
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Alanine aminotransferase (high)
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Albumin (low)
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Calcium (low)
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        7
    title
    Glucose (high)
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Potassium (low)
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Sodium (high)
  8. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Urate (high)
denoms
  1. counts
    1. group Id
      OG000
      value
      102
    units
    Participants
description
Counts of study participants with post-baseline chemistry laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 3.0. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category.
groups
  1. description
    Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
    id
    OG000
    title
    Brentuximab Vedotin
param Type
NUMBER
population Description
All participants who received treatment
reporting Status
POSTED
time Frame
up to 12 months
title
Chemistry Laboratory Abnormalities >/= Grade 3
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice